PD14-10 EVALUATION OF FINANCIAL TOXICITY ASSOCIATED WITH URINARY INCONTINENCE TREATMENT

Abstract

You have accessJournal of UrologyCME1 Apr 2023PD14-10 EVALUATION OF FINANCIAL TOXICITY ASSOCIATED WITH URINARY INCONTINENCE TREATMENT Azizou Salami, Benjamin Green, Anna Najor, Whitney Clearwater, and Nitya Abraham Azizou SalamiAzizou Salami More articles by this author , Benjamin GreenBenjamin Green More articles by this author , Anna NajorAnna Najor More articles by this author , Whitney ClearwaterWhitney Clearwater More articles by this author , and Nitya AbrahamNitya Abraham More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003261.10AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Urinary incontinence (UI) is a financially burdensome condition, costing US patients over 20 billion dollars annually. The individual financial burden has not been well described and warrants further study. Financial toxicity (FT) is the economic stress associated with the direct and indirect costs of treatment for a condition. Moderate-to-severe FT is associated with medication rationing and delaying care. This is the first study to characterize FT associated with the treatment of UI. METHODS: We performed a cross-sectional study using convenience sampling of new patients presenting with UI at an academic practice in the Bronx, NY from April to October of 2022. The validated COST tool (Comprehensive Score for financial Toxicity) was used to measure FT. “Low-FT” was defined as COST scores ≥26 and “moderate-to-severe FT” for COST scores <26, based on prior studies. The International Consultation on Incontinence Questionnaire (ICIQ) was used to measure UI severity. Chi-square and ANOVA tests were performed using SPSS v28. RESULTS: 79 patients were surveyed. All were female, with 30% identifying as Black and 45% as Latinx. The average age was 57.2±12.4. 83% of subjects had Medicare or Medicaid and 34% had private insurance. The mean ICIQ score was 14.1±3.2, and the mean COST score was 20.1±9.9. Most participants (65.8%) had “Moderate-to-severe FT” (COST scores <26). Compared to those with low-FT, those with moderate-to-severe FT were less likely to have private insurance (p=0.004) and more likely to use public transportation (p=0.004), have a greater number of unmet social needs (p<0.001), and a higher ICIQ score (p=0.009). The groups were not significantly different in age, race, ethnicity, or insurance type. CONCLUSIONS: 66% of women with UI in our study cohort experienced moderate-to-severe FT. Worse FT was associated with worse symptoms and increased barriers to healthcare. Given the high burden of FT in this patient population, urologists should consider routinely measuring FT in patients with UI and connect them to financial resources when necessary. Source of Funding: None © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e416 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Azizou Salami More articles by this author Benjamin Green More articles by this author Anna Najor More articles by this author Whitney Clearwater More articles by this author Nitya Abraham More articles by this author Expand All Advertisement PDF downloadLoading ...